An abnormal immediate increase in the intraocular pressure post-intravitreal injection in patients with Eales disease

Title: An abnormal immediate increase in the intraocular pressure post-intravitreal injection in patients with Eales disease

Authors: Anya Lev, Oskana Vladimir, Olga Nikolai

DOI: https://dx.doi.org/10.18535/jmscr/v11i11.13

Abstract

Introduction

In 1880, British ophthalmologist Henry Eales described Eales' disease for the first time⁽¹⁾. Recurrent vitreous hemorrhaging is a hallmark of Eales' disease⁽²⁾. The systemic anti- tuberculosis and the steroids usually control the disease and subsequently resolve the vitreous hemorrhage⁽³⁾, but when the vitreous hemorrhage persists, anti-VEGF is an option⁽⁴⁾.

References

Eales Primary retinal hemorrhage in young men. Ophthalmic Review. 1882;1:41-6.
Das T, Pathengay A, Hussain N, Biswas Eales’ disease: diagnosis and management. Eye. 2010;24(3):472-82.
Abdullah Unilateral Eales disease with presumed tubercular etiology, three case reports. Health Science Journal. 2020;14(4):1-5.
Patwardhan SD, Azad R, Shah BM, Sharma Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina. 2011;31(5):866-70.
Abdullah A Novel Approach to Prevent Intraocular Pressure Spikes and Reflux During Intravitreal Injections.

Corresponding Author

Anya Lev

Norilsk Health Care, Norilsk-Russia